Observational Study on the Efficacy and Adverse Effects of Foslevodopa Foscarbidopa Continuous Subcutaneous Infusion (FOCS)

Observational Study on the Efficacy and Adverse Effects of Foslevodopa Foscarbidopa Continuous Subcutaneous Infusion (FOCS) - Observational Study on the Efficacy and Adverse Effects of Foslevodopa Foscarbidopa Continuous Subcutaneous Infusion (FOCS)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000059699

Enrollment

100

Registered

2025-11-08

Start date

2025-10-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients treated with FOCS at the National Center Hospital, National Center of Neurology and Psychiatry, were included.

Exclusion criteria

Exclusion criteria: When the patient or their family declined to participate in this study.

Design outcomes

Primary

Measure	Time frame
Primary endpoint: The dropout rate following initiation of Foslevodopa Foscarbidopa Continuous Subcutaneous Infusion (FOCS). Secondary endpoints: Time to onset and types of FOCS related complications, as well as information regarding the management strategies adopted for these complications.	—

Countries

Japan

Contacts

Public ContactYohei Mukai

National Center Hospital, National Center of Neurology and Psychiatry Department of neurology

ymukai@yahoo.co.jp+81-42-341-2711

Outcome results